medications

How do cardiovascular outcomes differ between GLP-1 medications?

Semaglutide has the strongest cardiovascular outcome data. The SELECT trial demonstrated 20% reduction in major adverse cardiovascular events (MACE) for semaglutide 2.4mg in patients with established cardiovascular disease. The SUSTAIN-6 trial showed similar benefits for semaglutide 0.5mg and 1.0mg in type 2 diabetes patients. Liraglutide (LEADER trial) showed 13% MACE reduction. Tirzepatide cardiovascular outcome trials are ongoing. These benefits appear independent of weight loss, suggesting direct cardiovascular protective effects. The American Heart Association now recommends GLP-1 agonists with proven cardiovascular benefit as preferred add-on therapy for type 2 diabetes patients with atherosclerotic cardiovascular disease.

cardiovascularheart healthMACEclinical trials

Need provider-specific guidance?

Visit GLP1Search.com for cardiovascular research data

Compare Providers

Related questions

What is the difference between Ozempic and Wegovy? What is the difference between Mounjaro and Zepbound? How does semaglutide compare to tirzepatide for weight loss? What is Retatrutide and how is it different? What is the difference between daily and weekly GLP-1 injections?